natgillin/translations-raw huggingface dataset:
First, it will ultimately lower LDL-cholesterol and raise HDL-cholesterol levels, independent risk factors, thereby reducing the risk of mortality due to cardiovascular incidence subsequent to atheroma formation. 
Prvo, nužno će sniziti nivoe LDL-holesterola i povisiti nivoe HDL-holesterola, nezavisne rizične faktore, smanjujući tako rizik mortaliteta zbog kardiovaskularnih incidenata kao posljedica formiranja ateroma.
In one embodiment there is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in combination with at least one additional anti-tumour substance selected from the group consisting of cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, doxorubicin, pirarubicin, irinotecan, topotecan, amrubicin, epirubicin, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, bleomycin, olaparib, MEDI4736, AZDI775 and AZD6738. 
Spoj s formulom (I) ili njegova farmaceutski prihvatljiva sol, za upotrebu za liječenje raka, prema zahtjevu 15, naznačen time da se spoj s formulom (D, ili njegova farmaceutski prihvatljiva sol primjenjuje u kombinaciji s najmanje jednom dodatnom protu-tumorskom tvari odabranom iz skupine koju čine cisplatin, oksaliplatin, karboplatin, valrubicin, idarubicin, doksorubicin, pirarubicin, irinotekan, topotekan, amrubicin, epirubicin, etopozid, mitomicin, bendamustin, klorambucil, ciklofosfamid, ifosfamid, karmustin, melfalan, bleomicin, olaparib, MEDI4736, AZD1775 1 AZD6738.
If the dosage form according to the invention comprises the layered subunits (X) and (Y) and an optionally present separation layer (Z) in an at least partially vertical or horizontal arrangement, the dosage form preferably takes the form of a tablet, a coextrudate or a laminate. 
Ukoliko oblik davanja prema izumu ima slojevito oblikovane podjedinice (X) i (Y), kao i po potrebi prisutan razdjelni sloj (Z) barem djelomično vertikalno ili horizontalno smještene, on je pogodno u obliku tablete ili laminata.
contacting the diketone of formula 1 with an a-haloester, to obtain the compound of formula 2 wherein R' is a C1-C4 alkyl; 
DO po s a-haloesterom, da se dobije spoj formule 2 gdje R' je Ci-Ca alkil; b) transformiranje alkoholne skupine spoja formule 2 u odlazeću skupinu radi dobivanja spoja formule 3
An isolated antibody binding to human CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein the heavy chain variable domain comprises a CDR3 region comprising SEQ ID NO: 17, a CDR2 region comprising SEQ ID NO: 18, and a CDR1 region comprising SEQ ID NO: 19, and the light chain variable domain comprises a CDR3 region comprising SEQ ID NO: 20, a CDR2 region comprising SEQ ID NO: 21, and a CDR1 region comprising SEQ ID NO: 22. 
varijabilna domena jakog lanca obuhvaća područje CDR3 od SEQ ID NO:17, područje CDR2 od SEQ ID NO:18, i područje CDR1 od SEQ ID NO:19, te varijabilna domena slabog lanca obuhvaća područje CDR3 od SEQ ID NO:20, područje CDR2 od SEQ ID NO:21, i područje CDR1 od SEQ ID NO:22, ili
The dental post according to at least one of the claims 1 to 5, characterized in that said post is further composed of a composite resin matrix (9) comprising a dimethacrylate compound, in particular urethane dimethacrylate. 
Zubni most u skladu s najmanje jednim od patentnih zahtjeva 1 do 5, naznačen time što se navedeni most dodatno sastoji od matriksa od kompozitne smole (9), koja se sastoji od dimetakrilatnog spoja, osobito uretan-dimetakrilata.
▪ in step (e), separation is performed by floatation or air floating, optionally with the aid of ultrasound. 
• u koraku (e), razdvajanje se provodi flotacijom ili plutanjem na zraku, moguće uz pomoć ultrazvuka.
The present invention therefore provides a composition comprising a) a pharmaceutically effective amount of an acetate salt of caspofungin; b) a pharmaceutically acceptable amount of one or more pharmaceutically acceptable excipients effective to form a lyophilized cake; and c) a pharmaceutically effective amount of a buffering agent, wherein said buffering agent is succinate. 
PATENTNI ZAHTJEVI 1. Smjesa obuhvaća: a) farmaceutski djelotvornu količinu acetatne soli kaspofungina; b) farmaceutski prihvatljivu količinu jedne ili više farmaceutski prihvatljive pomoćne tvari djelotvorne za tvorbu liofilizirane torte; i c) farmaceutski djelotvornu količinu puferskog sredstva, gdje je pufersko sredstvo sukcinat.
a non-unitary formulation) comprising the acid addition salt and the one or more other therapeutic agent together with instructions for the extemporaneous association of the at least one compound to form a physical association of the two or more compounds/agents; or 
nejedinstveni pripravak) koji sadrži laktatnu sol i jedno ili više drugih terapeutskih sredstava zajedno s uputama za ekstremno povezivanje najmanje jednog spoja kako bi se formiralo fizičko povezivanje dvaju ili više spojeva / sredstava; ili e
The liquefied gas treatment system according to claim 2, wherein the third stream decompressed to a gas-liquid mixed state is returned to the cargo tank. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se treću struju, dekomprimiranu u plinsko-tekuće miješano stanje, vraća u spremnik za teret (11).
Example 5 Formulations Formulation A was prepared by wet granulation at −1.5 kg scale, yielding enough batch to prepare between 25 and 30 tablets, wherein all the tablets combined yield a total dose of about 30 mg sodium picosulfate, about 7 g of magnesium oxide, about 15 g of ascorbic acid, and about 100 mg of simethicone. 
HR P20190550 T1 pri čemu ekstragranularna frakcija uključuje askorbinsku kiselinu i drugu farmaceutski prihvatljivu komponentu pomoćne tvari, i pri čemu metoda uključuje, unutar razdoblja od 24 sata, oralno davanje bolesniku 25 do 30 tableta s tekućinom, iz čega proizlazi ukupna doza od otprilike 30 mg natrijeva pikosulfata, otprilike 7 g magnezijeva oksida, otprilike 15 g askorbinske kiseline i otprilike 100 mg simetikona.
Clause 29. An antisense oligonucleotide of any one of clauses 15-27, or a composition of clause 28, for use in a method of treatment of muscular dystrophy. 
Antisens oligonukleotid u skladu s bilo kojim od patentnih zahtjeva 1 do 17 ili pripravak u skladu s patentnim zahtjevom 18, naznačen time što je namijenjen upotrebi u postupku liječenja mišićne distrofije kod pacijenta.
wherein the effervescent tablet has a mass of 100 mg to 200 mg, a diameter of 5 to 10 mm, and a fracture strength of 10 N to 100 N. 
Orodisperzibilna pjenušava tableta u skladu s patentnim zahtjevom 1, naznačena time što ima promjer od 5 do 10 mm.
leucine (L) at amino acid position 103 using AHo numbering system (amino acid position 89 using Kabat numbering). 
-leucin (L) na poziciji 103 aminokiselina prema AHo sustavu numeriranja (pozicija 89 aminokiselina prema Kabat sustavu numeriranja).
A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule according to claim 6, optionally wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof. 
CDRH1 sekvencu amino kiseline SEK ID BR: 5;CDRH2 sekvencu amino kiseline SEK ID BR: 20; iCDRH3 sekvencu amino kiseline SEK ID BR: 44 pri čemu je, opcionalno, spomenuta stanica domaćina najmanje jedna izabrana od COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, HepG2, 653, SP2/0, 293, HeLa, mijeloma, ili stanica limfoma, ili bilo kojeg njihovog derivata, imortalizirane ili transformirane stanice.
can be hydrogen or the group wherein 
može biti vodik ili skupina [image] pri čemu
The membranes were diluted to a concentration of 0.6 mg/ml and 2U Adenosine deaminase (Roche)/ml membrane suspension was added. 
Membrane se razrijede do koncentracije od 0.6 mg/ml i doda se 2U Adenozin deaminaza (Roche)/ml membranska suspenzija.
Container (1) as claimed in one of the preceding claims, characterized in that the wall section (4) can be adjoined at an edge (7) of the pre-cut part, said edge extending in the envelope direction of the cup (1). 
Spremnik (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time da dio stijenke (4) može graničiti sa rubom (7) dijela koji prethodno odrezan, pri čemu se spomenuti rub proteže u smjeru omatanja čaše (1).
the catalyst comprises palladium on charcoal. 
(d) katalizator je paladij ili ugljen.
A mobile station apparatus (200) for which an space of a physical downlink control channel to search is defined based on a mobile station identity assigned from a base station apparatus (100), wherein the mobile station apparatus (200) performs decoding processing of a physical downlink control channel including a first mobile station identity and a physical downlink control channel including a second mobile station identity in a search space of a physical downlink control channel corresponding to the first mobile station identity when a plurality of mobile station identities is assigned from the base station apparatus (100). 
Uređaj mobilne stanice (200) koji je prilagođen za pretraživanje prostora pretraživanja za kontrolnim kanalom fizičke silazne veze, PDCCH, koji odašilje uređaj bazne stanice, naznačen time da uređaj mobilne stanice sadrži: sredstva podešena za provođenje obrade slijepog dekodiranja radi pretraživanja prostora pretraživanja za PDCCH, pri čemu je prostor pretraživanja definiran na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identitet druge mobilne stanice;
preparing a compound of formula 21 via Friedel-Craft reaction of a compound of formula 23 with a compound of formula 22; 
pripravu spoja s formulom 21 putem Friedel-Craftsove reakcije spoja s formulom 23 sa spojem s formulom 22;
The pharmaceutical composition of claim 1, wherein the composition comprises a therapeutically effective amount of the compound with the formula: butylated hydroxytoluene in an amount of about 0.001% to about 5% of the total weight of said composition, and optionally one or more of microcrystalline cellulose, starch, hydroxypropylcellulose, sodium starch glycolate, and magnesium stearate. 
13. Farmaceutski sastav iz patentnog zahtjeva 1, pri čemu sastav sadrži terapijski aktivnu količinu tvari formule: butiliranog hidroksitoluena u količini od oko 0.001% do oko 50% ukupne težine navedenog sastava i opcionalno jednog ili više od mikrokristalinične celuloze, škroba, hidroksipropilceluloze, natrijevog škrobnog glikolata i magnezijevog stearata.
D represents optionally substituted lower alkylene, optionally substituted lower alkenylene, optionally substituted lower alkynylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylnene, optionally substituted arylene or optionally substituted heteroarylene with the proviso that D is optionally further substituted by -E-G; 
D predstavlja po izboru supstituirani niži alkilen, po izboru supstituirani niži alkenilen, po izboru supstituirani niži alkinilen, po izboru supstituirani cikloalkilen, po izboru supstituirani heterocikloalkilnen, po izboru supstituirani arilen ili po izboru supstituirani heteroarilen uz uvjet da je D is po izboru dalje supstituiran s - E- G;
The 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivative according to claim 1, wherein R2 is halogen. 
Derivat 4-fenil-5-okso-1,4,5,6,7,8-heksahidrokinolina u skladu s patentnim zahtjevima 1-2, gdje R? je halogen.
The composition according to Embodiment 78, wherein the at least one binder is povidone. 
Smjesa prema zahtjevu 1, gdje je barem jedno vezivo povidon.
U is a single bond. 
U je jednostruka veza ili O,
When the active substance is embodied by ET-743, the reconstituted solution in such embodiments contains a concentration of ET-743 up to 500 µg/ml, with concentrations of about 50 µg/ml, about 100 µg/ml, and about 250 µg/ml being preferred. 
Kada je aktivna tvar u obliku ET-743, rekonstruirana otopina u takvim varijantama sadrži koncentraciju ET-743 do 500 ug/ml, sa poželjnim koncentracijama od oko 50 ug/ml, oko 100 ug/ml i oko 250 ug/ml.
scrubbing with water the exhaust gases in an exhaust gas scrubber (1, 1') in order to reduce sulphur dioxide emissions of the exhaust gases, said scrubbing producing wash water to be purified, i.e. 
HR P20180346 T1 PATENTNI ZAHTJEVI Postupak za obradu nečistoća u brodskim ispušnim plinovima kako bi se smanjilo emisije sumpornog dioksida, gdje se postupak sastoji u - čišćenju ispušnih plinova vodom u pročišćivaču ispušnih plinova (1, 1') kako bi se smanjilo emisije sumpornog dioksida u ispušnim plinovima, gdje se navedenim čišćenjem dobiva voda za ispiranje koju treba pročistiti, tj.
coupling a compound of formula (II) with a compound of formula (IV) in a suitable solvent, in the presence of a coupling agent, and optionally in the presence of an activating agent of the coupling agent; or 
kondenziranja spoja formule (II) sa spojem formule (IV) [image], u pogodnom otapalu, u prisutnosti kondenzacijskog sredstva, te izborno u prisutnosti aktivacijskog sredstva za kondenzacijsko sredstvo; ili
Should the protein of interest be formulated with a pharmaceutically acceptable carrier, the result of the process is a pharmaceutical composition. 
Ako se protein od interesa formulira s farmaceutski prihvatljivim nosačem, rezultat procesa predstavlja farmaceutsku kompoziciju.
Maltitol and isomalt have a dual function in the mixture. 
Maltitol i izomalt imaju dvojnu funkciju u smjesi.
The method of claim 18, wherein the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:8. 
(vi) CAR je kodirana sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8
The process according to claim 1, wherein the conversion of the compound of formula (IV) into the compound of formula (V) is carried out by means of the action of a sulphonyl chloride, a sulphonic anhydride or a sulphonimide. 
Postupak za industrijsku sintezu spoja formule (1) u skladu s patentnim zahtjevom 1, naznačen time, da se pretvaranje spoja formule (IV) u spoj formule (V) izvodi djelovanjem sulfonil klorida, sulfonskog anhidrida ili sulfonamida.
The method as in embodiment 3, wherein the first portion of the surface (2) corresponds to upper surface portions (17a) and the second portion of the surface (2) corresponds to lower surface portions (17b). 
Postupak prema zahtjevu 3, naznačen time što prvi dio površine (2) odgovara gornjim dijelovima površine (17a) i drugi dio površine (2) odgovara donjim dijelovima površine (17b).
After 43.5 hours the consumption of hydrogen stops and the procedure is terminated. 
Nakon 43,5 sati s potrošnjom vodika se prestaje, a postupak se prekida.
A composition according to claim 1 or claim 2, wherein the effective temperature is approximately equal to or less than about 25°C. 
Sastav prema zahtjevu 1, gdje je nivo proizvoda razgradnje H168/79 u sastavu približno jednak ili manji od oko 1.5% kada se sastav čuva na odgovarajućoj temperaturi.
An isolated monoclonal antibody, or an antigen-binding portion thereof, or an antibody fragment which binds an epitope on human CADM1 and comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 19, 20, or 21 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 22, 23, or 24. 
HR P20171274 T1 PATENTNI ZAHTJEVI 1. Izolirano monoklonsko antitijelo, ili dio koji veže antigen, ili fragment antitijela koji veže epitop na ljudski CADMI 1 uključuje varijabilnu regiju teškog lanca amino kiselinske sekvence iznijetu u SEK ID BR: 19, 20, ili 21 varijabilnu regiju lakog lanca amino kiselinske sekvence iznijetu u SEK ID BR: 22, 23, ili 24.
The optoelectronic device as claimed in claim 1, wherein the first semiconductor material is a p-type semiconductor material and the second semiconductor material is an n-type semiconductor material. 
Optoelektronički uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi poluvodički materijal (316) je p-tip poluvodičkog materijala, a drugi poluvodički materijal (317) je n-tip poluvodičkog materijala.
Pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative in concentration comprised between 2.4 and 5-2 mg/ml aluminium ion wherein: 
Farmaceutska smjesa za parenteralnu primjenu kao cjepivo, naznačena time, što sadrži monoklonsko antitijelo i, kao adjuvans, derivat aluminija u koncentraciji od 2.4 do 5.2 mg/ml iona aluminija, u kojoj:
A compound for use according to Claim 7, wherein at least one other therapeutic agent is imiglucerase or 1,5-(butylimino)-1,5-dideoxy-D-glucitol. 
Spoj za uporabu prema zahtjevu 7, naznačen time što je barem jedno drugo terapeutsko sredstvo imigluceraza ili 1,5-(butilimino)-1,5-dideoksi-D-glucitol.
Therefore in one aspect of the present invention, high purity pravastatin is synthesized by using pure compactin, which is obtained by at least one step of purifying the compactin prior to pravastatin synthesis, or by selecting a batch of pure compactin. 
Prema tome, u jednom ostvarenju predstavljenog izuma, pravastatin visoke čistoće se sintetizira pomoću uporabe čistog kompaktina, koji se dobije u najmanje jednom koraku pročišćavanja kompaktina prije sinteze pravastatina, ili se odabire serija čistog kompaktina.
The siRNA according to the aforementioned 1), which is selected from the following (a) to (s): 
sIRNA koja ima punu dužinu od 21 do 23 nukleotida, naznačena time, da je odabrana od sljedećih (a) do (0):
The method according to any one of claims 1 to 3, wherein the data slices have an arbitrary bandwidth in frequency direction in the signal frame. 
Postupak prema zahtjevu 1 ili zahtjevu 2, gdje podatkovni komadi imaju arbitrarnu širinu pojasa u smjeru frekvencije u okviru signala.
The mono-lysine salt or solvate thereof according to claim 1, wherein said A is selected from the group consisting of: and 
Mono-lizinska sol ili njezin solvat prema zahtjevu 1, naznačena time, da je spomenuti A odabran iz skupine koja sadrži: [image] [image] i [image]
In some embodiments, the polypeptides can exhibit a fibrinolytic activity that is inhibited by a2-antiplasmin at a rate that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by a2-mtiplasmin. 
Polipeptid prema zahtjevu 8, naznačen time da polipeptid pokazuje fibrinolitičku aktivnost koja je inhibirana s a2- antiplazminom pri stupnju inhibicije koji je najmanje oko 5 puta brži nego što je stupanj inhibicije fibrinolitičke aktivnosti mini-plazmina sa 62-antiplazminom.
The closure for a vial or a plunger for a hypodermic syringe of claim 1 wherein the base thermoplastic elastomer is compounded with 3-15 wt. % of a colourant master batch comprising an LDPE carrier with 15-20 wt. % of pigment of a colour Panton 5497C, 556C, 5565C, 563C, 570C, 5555C or a similar grey or grey-green colour. 
Zatvarač za bočicu ili klip za potkožnu špricu u skladu s patentnim zahtjevom 1, koji sadržava CawitonTM PR5947, koji je pomiješan s 3 - 15 masenih % glavne šarže sa sredstvom za bojenje koja sadržava LDPE kao nosilac s 15 20 masenih % pigmenta boje Pantone 5497C, 556C, 5565C, 563C, 570C ili 555C.
The binding protein of claim 4 wherein said maleimide-coupled polyethylene glycol is a-[3-(3-maleimido-1-oxopropyl)amino]propyl-w-methoxy-polyoxyethylene, and wherein the polyethylene glycol moiety has a molecular weight of at least 10 kDa. 
Vezivni protein sukladno patentnom zahtjevu 4, naznačen time, da navedeni polietilenglikol kuplovan s maleimidom je a-[3-(3-maleimido-1-oksopropil) amino] propil-w-metoksi-polioksietilen, i pri čemu je polietilenglikolni dio molekularnu težinu od najmanje 10 kDa.
In other words, in the tangency zones 38 there is no fixed obstacle which opposes the passage of material from the grinding volume 28 1 of one rotor 30 1 to the grinding volume 28 2 of the adjacent rotor 30 2. In the light of the above comments and with particular reference to FIGS. 
Mlin (20) sukladno prethodnom zahtjevu, pri čemu u zonama tangencije (38) nema čvrste pregrade koja sprječava prijelaz tijela od jednog volumena za mljevenje (281) rotora (30; do volumena za mljevenje (282) susjednog rotora
Process according to claim 1, in which the alcohologenic microorganism is selected from among the microorganisms of the genus Saccharomyces, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Saccharomyces uvarum, Saccharomyces diastaticus, Kluyveromyces fragilis, Candida shehatae, Pichia stipitis, Pachysolen tannophilis, Zymomonas mobilis, Clostridium, and Escherichia coli. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time što je alkohologeni mikroorganizam odabran od mikroorganizama roda Saccharomyces, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Saccharomyces uvarum, Saccharomyces diastaticus, Kluyveromyces fragilis, Candida shehatae, Pichia stipitis, Pachysolen tannophilis, Zymomonas mobilis, Clostridium, Escherichia coli.
a heavy chain region corresponding to SEQ ID NO: 101 and a light chain region corresponding to SEQ ID NO: 102. 
regiju teškog lanca koja odgovara SEQ ID NO: 101 i regiju lakog lanca koja odgovara SEQ ID NO: 102.
The antimicrobial composition according to claim 2 wherein the manuka honey has a methylglyoxal concentration of greater than about 30mg/kg, than about 38mg/kg, than about 40mg/kg, about 50mg/kg, about 60mg/kg, about 70mg/kg, about 80mg/kg, about 90mg/kg, about 100mg/kg, about 150mg/kg, about 200mg/kg, about 250mg/kg, about 300mg/kg, about 350mg/kg, about 400mg/kg, about 450mg/kg, about 500mg/kg, about 550mg/kg, about 600mg/kg, about 650mg/kg, about 700mg/kg, about 750mg/kg, about 800mg/kg, about 850mg/kg, about 900mg/kg, about 950mg/kg, greater than about 1000mg/kg, greater than about 1100mg/kg, greater than about 1200mg/kg, greater than about 1300mg/kg, greater than about 1400mg/kg, greater than about 1500mg/kg, greater than about 1600mg/kg, greater than about 1700mg/kg, greater than about 1800mg/kg, greater than about 1900mg/kg, or about 2000mg/kg, or wherein the manuka honey has an NPA rating greater than 10, than 15, than 20, than 25, 26, 27, 28, 29, 30, than 31, 32, 33, 34, or greater than 35. 
mg/kg, nego oko 150 mg/kg, nego oko 200 mg/kg, nego oko 250 mg/kg, nego oko mg/kg, nego oko 350 mg/kg, nego oko 400 mg/kg, nego oko 450 mg/kg, nego oko 500 mg/kg, nego oko 550 mg/kg, nego oko 600 mg/kg, nego oko 650 mg/kg, nego oko 700 mg/kg, nego oko 750 mg/kg, nego oko 800 mg/kg, nego oko 850 mg/kg, nego oko 900 mg/kg, nego oko 950 mg/kg, veću nego oko 1000 mg/kg, veću nego oko 1100 mg/kg, veću nego oko 1200 mg/kg, veću nego oko 1300 mg/kg, veću nego oko 1400 mg/kg, veću nego oko 1500 mg/kg, veću nego oko 1600 mg/kg, veću nego oko 1700 mg/kg, veću nego oko 1800 mg/kg, veću nego oko 1900 mg/kg ili veću nego oko 2000 mg/kg, ili manuka med ima NPA-procjenu veću od 10, od 15, od 20, od 25, 26, 27, 28, 29, 30, veću od 31, 32, 33, 34 ili veću od 35.
A process for the preparation of lenalidomide, comprising the catalytic reduction of 3-(1-oxo-4-nitro-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, comprising: 
Postupak pripreme lenalidomida, obuhvaća katalitičku redukciju 3-(1-okso-4-nitro-1,3-dihidro-izoindol-2-il)-piperidin-2,6-diona koja obuhvaća:
2 to 4 further comprising a chelating agent which is selected from a group comprising Disodium EDTA and the like, or any combination thereof, and added in an amount from about 0.05% (w/w) to 1% (w/w). 
Medicinska krema prema patentnim zahtjevima 1 i 3 do 5, naznačena time, da nadalje sadrži agens za keliranje koji se odabire iz skupine koja sadrži dinatrijevu EDTA i slične, ili bilo koju njihovu kombinaciju i dodaje u količini od oko 0,05% (tež.) do 1% (tež.).
The term LIGAND shall mean an endogenous, naturally occurring molecule specific for an endogenous, naturally occurring receptor. 
Izraz LIGAND će značiti endogenu molekulu koja se prirodno nalazi i koja je specifična za endogeni receptor koji se prirodno nalazi.